Session Chair Profile

M.D., Chancellor Emeritus, Duke University

Ralph Snyderman, MD is Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine in the Duke University School of Medicine. He served as Chancellor for Health Affairs and Dean of the School of Medicine at Duke University from 1989 to July 2004 and led the transition of this excellent medical center into an internationally recognized leader of academic medicine. He oversaw the development of the Duke University Health System, one of the most successful integrated academic health systems in the country, and served as its first President and Chief Executive Officer. Dr. Snyderman has played a leading role in the conception and development of Personalized Health Care, an evolving model of national health care delivery. He was amongst the first to envision and articulate the need to move the current focus of health care from the treatment of disease-events to personalized, predictive, preventive, and participatory care that is focused on the patient. Dr. Snyderman is the recipient of numerous awards recognizing his contributions to research and to developing more rational models of health care. In 2012, he received the David E. Rogers Award from the Association of American Medical Colleges who referred to Snyderman as “the father of personalized medicine.”


Advancing Precision Medicine into Practice: Clinical Models
Precision medicine technologies are rapidly providing new capabilities to improve the delivery of health care but to do so they need to be efficiently adopted into practice. Current clinical approaches and workflows are not well designed to adopt precision technologies and clinical redesign is needed to advance the adoption of precision medicine into practice. Suggestions for such clinical approaches and work flows will be presented.

Session Abstract

Session Synopsis: This panel promises an exciting discussion around the interplay between universities and entrepreneurship, the creation of intellectual property and building biotech. Different leaders across academia, venture capital, and companies will join this discussion of how to connect university activities and researchers with the emerging biotech sector for successful business development that can catapult the Research Triangle beyond Silicon Valley.